Breaking News
Pfizer Announces New Chief Business Innovation Officer Aamir Malik
Pfizer Inc. (NYSE: PFE) today announced that Aamir Malik has joined the company as Executive Vice President and Chief Business Innovation Officer. Mr. Malik will be a member of Pfizer’s Executive Leadership Team reporting to Chairman and Chief Executive Officer, Albert Bourla. Mr. Malik joins Pfizer from McKinsey & Company, where he most recently served as the Managing Partner responsible for the firm’s U.S. operations. Previously, he led the firm’s Global Pharmaceuticals & Medical Products practice.
Mr. Malik succeeds John Young, Executive Vice President and Chief Business Officer, who recently announced his intent to retire after a 34-year career at Pfizer. Mr. Malik begins his role on August 30, 2021 and will work with John to ensure a seamless transition.
At Pfizer, Mr. Malik will oversee the company’s strategy, business development, portfolio management, pipeline prioritization, and formation of new business ventures, as well as the advancement of innovative access partnerships with payers and governments around the world.
“We are delighted to welcome Aamir Malik to our executive leadership team in this important role as we enter the next era of innovation for Pfizer and continue our pursuit of both cutting-edge science and opportunities to reimagine how we do business for the benefit of patients and society,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “Aamir brings with him 25 years of experience developing innovative growth strategies, guiding mergers and acquisitions, and implementing high-impact programs to improve patients’ lives and transform performance for life science companies. He is the ideal leader to drive these efforts.”
Mr. Malik earned a Bachelor of Science in finance from Indiana University and currently serves on the University’s Kelley School of Business Dean’s Council. He is an active advocate for bettering the lives of people with food allergies and has lived and worked globally including in the U.S., Europe, Asia, Latin America, and Africa.
Bourla added: “Let me take this opportunity to thank John for his incredible career at Pfizer and for his exemplary leadership, dedication, and passion for helping patients and advancing our purpose, which has had a huge impact on our business. We wish him all the best in his retirement.”
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more